Bibliographic information
GuidelineAntiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings : towards universal access : recommendations for a public health approach
Year of Publication2006
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
Originally developed
Efavirenz should be used as the preferred non-nucleoside reverse transcriptase inhibitor in patients starting ART while on antituberculosis treatment
Recommended in favor
Strong
Certainty of evidence
High
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO policy on collaborative TB/HIV activities : guidelines for national programmes and other stakeholders
Year2012
InstitutionWHO